|
Marknaden stängd -
Andra börsplatser
|
Efter stängning 02.00.00 | |||
| 27,58 USD | +0,40 % |
|
27,77 | +0,69 % |
| 02-13 | Actinium Pharmaceuticals, Inc. meddelar ändringar av huvudansvarig finanschef från och med den 27 februari 2026 | CI |
| 02-13 | USA viktiga bolag klockan 16.16 - Ingersoll-Rand stiger 3,6 procent | FW |
Försäljning 2024 per affärssegment
Försäljning 2024 efter Geografi
Historisk fördelning av intäkter per affärssegment
EBT: Fördelning efter verksamhetssegment
| Skatteperiod: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Global Biopharmaceuticals Business (Biopharma) | 41,91 md | 79,56 md | 98,99 md | 57,19 md | 62,4 md | |||||
Interest Expense | −1,45 md | - | - | - | - | |||||
Income Tax Expense | 477 mn | - | - | - | - | |||||
Total Assets | 154 md | - | - | - | - | |||||
CAPEX | −2,79 md | - | - | - | - | |||||
EBT | 7,5 md | 40,23 md | 57,15 md | 30,63 md | 28,14 md | |||||
D&A | 4,76 md | 1,44 md | 813 mn | 882 mn | 1,36 md | |||||
Net Income | 9,62 md | - | - | - | - | |||||
Upjohn | - | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Innovative Health (IH) | - | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Essential Health (EH) | - | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Global Vaccines, Oncology and Consumer Healthcare (VOC) | - | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Global Innovative Pharmaceutical (GIP) | - | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Life Sciences Tools and Services | ||||||||||
Pfizer Centreone (PC1) | - | - | - | - | 1,15 md | |||||
Pfizer Ignite | - | - | - | - | 82 mn | |||||
EBT | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
EBT | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
EBT | - | −2,29 md | −3,61 md | −3,92 md | −5,51 md | |||||
D&A | - | 87 mn | 36 mn | - | - | |||||
EBT | - | −52 mn | −832 mn | −1,87 md | −1,94 md | |||||
D&A | - | - | −20 mn | −11 mn | 12 mn | |||||
EBT | - | −3,18 md | - | - | - | |||||
D&A | - | 3,07 md | - | - | - | |||||
EBT | - | - | −3,61 md | −4,73 md | −5,29 md | |||||
D&A | - | - | 3,61 md | 4,73 md | 5,29 md | |||||
Pharmaceutical Contract Manufacturing Services | ||||||||||
Other business activities | - | 1,73 md | 1,34 md | 1,31 md | - | |||||
EBT | - | −10,4 md | −14,37 md | −19,05 md | −7,38 md | |||||
D&A | - | 598 mn | 626 mn | 654 mn | 340 mn |
Historik över geografisk fördelning av omsättning
| Skatteperiod: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 21,71 md | 29,75 md | 42,47 md | 27,09 md | 38,69 md | |||||
Total Assets | 7,82 md | 8,38 md | 9,18 md | 10,67 md | 9,75 md | |||||
Developed Markets | - | - | - | - | 16,06 md | |||||
Total Assets | - | - | - | - | 7,19 md | |||||
Emerging Markets | 8,37 md | 20,7 md | 20,1 md | 12 md | 8,88 md | |||||
Total Assets | 890 mn | 1,06 md | 1,41 md | 1,76 md | 1,46 md | |||||
Developed Europe | 7,79 md | 18,34 md | 21,98 md | 11,65 md | - | |||||
Total Assets | 4,78 md | 5,09 md | 5,39 md | 6,22 md | - | |||||
International | 4,04 md | 12,51 md | 15,78 md | 7,76 md | - | |||||
Total Assets | 413 mn | 347 mn | 293 mn | 290 mn | - |
- Börsen
- Aktier
- PFE Aktie
- Finanser Pfizer Inc.
- Affärssegment
Välj din utgåva
All finansiell information anpassad till den nationella nivån
MarketScreener is also available in this country: United States.
Switch edition















